Dianthus Therapeutics, Inc. /DE/ Net Fee Amt
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Net Fee Amt of $69.05 thousand as of 2026-09-17, per its S-3ASR filed 2026-09-18.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-18
- 2026-09-17: Net Fee Amt $69.05K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-17 | $69.05K S-3ASR · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |